2.95
                                            
                                Überblick
                                Nachrichten
                                Preisverlauf
                                    Optionskette
                                Financials
                                    Warum fällt ESPR?
                                Forum
                                Prognose
                                    Aktiensplit
                        
                        Schlusskurs vom Vortag:
              $2.97
            Offen:
              $3
            24-Stunden-Volumen:
                3.83M
            Relative Volume:
              0.58
            Marktkapitalisierung:
                $594.79M
            Einnahmen:
              $116.33M
            Nettoeinkommen (Verlust:
              $-209.25M
            KGV:
              -1.3915
            EPS:
                -2.12
            Netto-Cashflow:
                $-135.49M
            1W Leistung:
              +1.72%
            1M Leistung:
              -10.61%
            6M Leistung:
                +170.64%
            1J Leistung:
              +45.32%
            Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
                  
                      Esperion Therapeutics Inc
                    
                Sektor
                  Telefon
                  
                      734-887-3903
                    
                Adresse
                  
                      3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
                    
                Vergleichen Sie ESPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV | 
|---|---|---|---|---|---|---|
| 
                         
                          
                                ESPR
                            
                             
                        Esperion Therapeutics Inc 
                           | 
                    2.95 | 687.92M | 116.33M | -209.25M | -135.49M | -2.12 | 
| 
                         
                          
                                ZTS
                            
                             
                        Zoetis Inc 
                           | 
                    144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 | 
| 
                         
                          
                                TAK
                            
                             
                        Takeda Pharmaceutical Co Adr 
                           | 
                    13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 | 
| 
                         
                          
                                HLN
                            
                             
                        Haleon Plc Adr 
                           | 
                    9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 | 
| 
                         
                          
                                TEVA
                            
                             
                        Teva Pharmaceutical Industries Ltd Adr 
                           | 
                    20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 | 
| 
                         
                          
                                UTHR
                            
                             
                        United Therapeutics Corp 
                           | 
                    438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 | 
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung | 
|---|---|---|---|
| 2024-12-18 | Eingeleitet | Goldman | Neutral | 
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight | 
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform | 
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral | 
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral | 
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform | 
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy | 
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform | 
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform | 
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral | 
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral | 
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy | 
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight | 
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform | 
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral | 
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy | 
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral | 
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight | 
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold | 
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform | 
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight | 
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold | 
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell | 
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral | 
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform | 
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight | 
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral | 
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy | 
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy | 
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform | 
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral | 
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral | 
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell | 
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral | 
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral | 
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral | 
| 2019-01-07 | Bestätigt | Needham | Strong Buy | 
| 2018-12-13 | Eingeleitet | Goldman | Sell | 
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform | 
| 2018-10-16 | Eingeleitet | BTIG Research | Buy | 
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy | 
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform | 
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight | 
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform | 
                    Alle ansehen
                    
                  
                Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Smart tools for monitoring Esperion Therapeutics Inc.’s price action2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com
Why retail investors favor Esperion Therapeutics Inc. stockJuly 2025 PostEarnings & Daily Price Action Insights - newser.com
Can Esperion Therapeutics Inc. stock reach $100 price targetJuly 2025 Trends & Real-Time Market Sentiment Alerts - newser.com
Should you wait for a breakout in Esperion Therapeutics Inc.July 2025 Intraday Action & Community Consensus Trade Alerts - newser.com
How Esperion Therapeutics Inc. stock benefits from global expansion2025 Top Gainers & Technical Pattern Based Signals - newser.com
Will Esperion Therapeutics Inc. stock return to pre crisis levelsQuarterly Market Review & Real-Time Volume Trigger Notifications - newser.com
Using AI based signals to follow Esperion Therapeutics Inc.Quarterly Profit Summary & Weekly High Return Stock Forecasts - newser.com
Will Esperion Therapeutics Inc. stock outperform international peersJuly 2025 Action & Daily Volume Surge Signals - newser.com
Esperion to Participate in Jefferies Global Healthcare ConferenceLondon - The Manila Times
Esperion (NASDAQ: ESPR) to webcast Nov 18 Jefferies Global Healthcare Conference presentation - Stock Titan
Can volume confirm reversal in Esperion Therapeutics Inc.Quarterly Market Summary & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-11-03 04:49:46 - newser.com
Relative strength of Esperion Therapeutics Inc. in sector analysis2025 Winners & Losers & Fast Entry High Yield Tips - newser.com
Published on: 2025-11-03 03:31:08 - newser.com
Will Esperion Therapeutics Inc. (0ET) stock benefit from mergersMarket Sentiment Report & Technical Analysis for Trade Confirmation - newser.com
Why analysts raise outlook for Esperion Therapeutics Inc. (0ET) stockTrade Performance Summary & Target Return Focused Stock Picks - newser.com
Can Esperion Therapeutics Inc. stock double in next 5 years2025 Geopolitical Influence & Accurate Buy Signal Alerts - newser.com
Why Esperion Therapeutics Inc. stock is favored by top institutionsPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
Can Esperion Therapeutics Inc. stock deliver surprise earnings beatMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
Published on: 2025-11-03 01:10:01 - newser.com
Why Esperion Therapeutics Inc. is moving todayJuly 2025 Retail & Capital Efficiency Focused Ideas - newser.com
Is Esperion Therapeutics Inc. stock reversal real or fakeLong Setup & Expert Verified Movement Alerts - newser.com
Will earnings trigger a reversal in Esperion Therapeutics Inc.IPO Watch & Weekly High Return Stock Opportunities - newser.com
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsPortfolio Gains Report & Verified Stock Trade Ideas - newser.com
How high can Esperion Therapeutics Inc. stock goPortfolio Return Summary & Real-Time Buy Signal Alerts - newser.com
Why analysts remain bullish on Esperion Therapeutics Inc. stock2025 Sector Review & Real-Time Market Sentiment Reports - newser.com
Esperion Therapeutics (NASDAQ:ESPR) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Multi asset correlation models including Esperion Therapeutics Inc.Buy Signal & Verified Short-Term Plans - newser.com
Will Esperion Therapeutics Inc. stock gain from lower inflationJuly 2025 Weekly Recap & Fast Exit and Entry Strategy Plans - newser.com
Esperion Therapeutics (ESPR) to Release Quarterly Earnings on Thursday - MarketBeat
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
        In Yahoo öffnen
        |
        In Google öffnen
            |
            In Finviz öffnen
        |
        In MarketWatch öffnen
            |
            Öffnen Sie in EDGAR    
        |
        Offen in Reuters
    
    
                Kapitalisierung:
                 
                  | 
                Volumen (24h):